An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents

Por Péron, Julien, Polivka, Valentine, Chabaud, Sylvie, Poupart, Marc, Ceruse, Philippe, Ramade, Antoine, Girodet, Didier, Zrounba, Philippe, Fayette, Jérôme
Publicado em 2014

Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma

Por Fayette, Jérôme, Molin, Yann, Lavergne, Emilie, Montbarbon, Xavier, Racadot, Séverine, Poupart, Marc, Ramade, Antoine, Zrounba, Philippe, Ceruse, Philippe, Pommier, Pascal
Publicado no Drug Des Devel Ther (2015)

Carboplatin in combination with weekly Paclitaxel as first-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma unfit to EXTREME schedule

Por Pêtre, Adeline, Dalban, Cécile, Karabajakian, Andy, Neidhardt, Eve-Marie, Roux, Pierre Eric, Poupart, Marc, Deneuve, Sophie, Zrounba, Philippe, Fayette, Jérome
Publicado no Oncotarget (2018)

Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients

Por Fayette, Jérôme, Fontaine-Delaruelle, Clara, Ambrun, Alexis, Daveau, Clémentine, Poupart, Marc, Ramade, Antoine, Zrounba, Philippe, Neidhardt, Eve-Marie, Péron, Julien, Diallo, Alpha, Céruse, Philippe
Publicado no Oncotarget (2016)